Change in Ocular Flora Resistance From Repeated Topical Antibiotic Use
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01181713|
Recruitment Status : Completed
First Posted : August 13, 2010
Last Update Posted : March 18, 2021
|Condition or disease|
|Increased Drug Resistance Infection Resistant to Quinolones and Fluoroquinolones|
Treatment with intravitreal (IVT) injections has increased during the last several years as evidence has accumulated demonstrating the efficacy of anti-vascular endothelial growth factor agents in the treatment of neovascular age-related macular degeneration (AMD) and various retinal vascular diseases.
Although IVT injections are generally safe, infectious endophthalmitis is a rare but devastating complication, and the risk of morbidity and vision loss from endophthalmitis is high. The objective is to examine the change in antibiotic resistance of ocular surface flora with repeated prophylactic use of antibiotics after IVT injection for AMD.
Yin, V. T., Weisbrod, D. J., Eng, K. T., Schwartz, C., Kohly, R., Mandelcorn, E., Lam, W., Daneman, N., Simor, A., & Kertes, P. J. (2013). Antibiotic resistance of ocular surface flora with repeated use of a topical antibiotic after intravitreal injection. JAMA ophthalmology, 131(4), 456-461.
|Study Type :||Observational|
|Actual Enrollment :||200 participants|
|Official Title:||Antibiotic Resistance of Ocular Surface Flora After Continued Use of Topical Antibiotics Post Intravitreal Injections|
|Study Start Date :||June 2010|
|Actual Primary Completion Date :||September 2011|
|Actual Study Completion Date :||December 2011|
No prophylactic antibiotic post intravitreal injection
Group treated with 3 day course of prophylactic topic antibiotic, fourth generation fluoroquinolones, after each intravitreal injection
- ocular flora resistance to 4th generation fluoroquinolone [ Time Frame: 1 year ]Outcome will examine the change in amount, type and antibiotic resistance profile of ocular surface flora over the 3 months. Charcoal swab of the conjunctiva will be cultured, organisms grown will be identified and resistance to moxifloxacin will be quantified by minimal inhibitory resistance (MIC).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01181713
|Sunnybrook Health and Sciences Centre|
|Toronto, Ontario, Canada, M4N 3M5|
|Study Chair:||Peter Kertes, MD, FRCSC||Sunnybrook Health Sciences Centre|
|Study Director:||Vivian T Yin, MD||University of Toronto|
|Study Director:||Daniel Weisbrod, MD, FRCSC||Sunnybrook Health Sciences Centre|